The Beauty Health Company: A Compelling Mid To Long-Term Growth Story

Oct. 12, 2022 3:41 PM ETThe Beauty Health Company (SKIN)1 Comment
JP Research profile picture
JP Research


  • The Beauty Health Company’s new mid-term targets highlight the impressive (but achievable) growth opportunities at hand.
  • As the model benefits from operating leverage, more revenue growth should yield significant margin expansion as well.
  • The stock isn't cheap but growth rarely is; with successful execution, the company should grow into its valuation over time.

Facial aesthetics surgery treatment

Group4 Studio

In conjunction with its 2022 investor day (webcast here), the Beauty Health Company (NASDAQ:SKIN), a provider of skin treatment solutions, outlined a new mid-term financial plan through 2025 that screened favorably even relative to the optimistic

Data by YCharts

Mid-Term Targets

The Beauty Health Company

Syndeo Outlook

The Beauty Health Company

Sephora Partnership

The Beauty Health Company

M&A Philosophy

The Beauty Health Company

This article was written by

JP Research profile picture
A passionately curious analyst.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.